全文获取类型
收费全文 | 558篇 |
免费 | 46篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 16篇 |
妇产科学 | 5篇 |
基础医学 | 109篇 |
口腔科学 | 26篇 |
临床医学 | 79篇 |
内科学 | 96篇 |
皮肤病学 | 16篇 |
神经病学 | 35篇 |
特种医学 | 37篇 |
外科学 | 69篇 |
综合类 | 4篇 |
预防医学 | 31篇 |
药学 | 36篇 |
中国医学 | 1篇 |
肿瘤学 | 42篇 |
出版年
2021年 | 7篇 |
2020年 | 6篇 |
2019年 | 7篇 |
2018年 | 11篇 |
2017年 | 8篇 |
2016年 | 7篇 |
2015年 | 14篇 |
2014年 | 12篇 |
2013年 | 20篇 |
2012年 | 24篇 |
2011年 | 21篇 |
2010年 | 22篇 |
2009年 | 16篇 |
2008年 | 29篇 |
2007年 | 19篇 |
2006年 | 25篇 |
2005年 | 18篇 |
2004年 | 23篇 |
2003年 | 16篇 |
2002年 | 15篇 |
2001年 | 12篇 |
2000年 | 18篇 |
1999年 | 7篇 |
1998年 | 14篇 |
1997年 | 15篇 |
1996年 | 17篇 |
1995年 | 8篇 |
1994年 | 8篇 |
1993年 | 6篇 |
1992年 | 14篇 |
1991年 | 13篇 |
1990年 | 11篇 |
1989年 | 17篇 |
1988年 | 10篇 |
1987年 | 10篇 |
1986年 | 9篇 |
1984年 | 4篇 |
1983年 | 8篇 |
1980年 | 4篇 |
1979年 | 7篇 |
1976年 | 4篇 |
1974年 | 7篇 |
1973年 | 4篇 |
1972年 | 6篇 |
1970年 | 3篇 |
1969年 | 3篇 |
1968年 | 3篇 |
1967年 | 5篇 |
1966年 | 6篇 |
1965年 | 4篇 |
排序方式: 共有607条查询结果,搜索用时 31 毫秒
1.
2.
3.
Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study 总被引:31,自引:0,他引:31
H D Lewis J W Davis D G Archibald W E Steinke T C Smitherman J E Doherty H W Schnaper M M LeWinter E Linares J M Pouget S C Sabharwal E Chesler H DeMots 《The New England journal of medicine》1983,309(7):396-403
We conducted a multicenter, double-blind, placebo-controlled randomized trial of aspirin treatment (324 mg in buffered solution daily) for 12 weeks in 1266 men with unstable angina (625 taking aspirin and 641 placebo). The principal end points were death and acute myocardial infarction diagnosed by the presence of creatine kinase MB or pathologic Q-wave changes on electrocardiograms. The incidence of death or acute myocardial infarction was 51 per cent lower in the aspirin group than in the placebo group: 31 patients (5.0 per cent) as compared with 65 (10.1 per cent); P = 0.0005. Nonfatal acute myocardial infarction was 51 per cent lower in the aspirin group: 21 patients (3.4 per cent) as compared with 44 (6.9 per cent); P = 0.005. The reduction in mortality in the aspirin group was also 51 per cent--10 patients (1.6 per cent) as compared with 21 (3.3 per cent)--although it was not statistically significant; P = 0.054. There was no difference in gastrointestinal symptoms or evidence of blood loss between the treatment and control groups. Our data show that aspirin has a protective effect against acute myocardial infarction in men with unstable angina, and they suggest a similar effect on mortality. 相似文献
4.
5.
乳腺管状小叶癌(Tubulolobular carcinoma,TLC)最初是被作为小叶癌的管状变型。作者总结了27例TLC的组织学、免疫表型和临床特征,并与纯小管癌和经典型小叶癌进行了比较。此组患者年龄43-79岁(中位年龄60岁)。1例双侧乳腺受累,5例病变为多灶性。肿瘤直径0.5-2.5cm,色灰褐,质硬。组织学观察:TLC的肿瘤细胞形成管状和条索状两种结构模式并相互混杂,且两者比例相当(统称为管状小叶模式)。 相似文献
6.
7.
8.
Kimberly Mascia Larry Borish James Patrie John Hunt C Douglas Phillips John W Steinke 《Annals of allergy, asthma & immunology》2005,94(6):652-657
BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is a disease of intense eosinophilic inflammation that can produce fibrosis, hyperplasia, and remodeling. OBJECTIVE: To investigate the usefulness of quantifying severity of chronic hyperplastic eosinophilic sinusitis in predicting the presence of AERD. METHODS: Data were compared between asthmatic patients who reported exacerbations after aspirin ingestion and those who did not. The primary outcome measure was severity of sinusitis using a validated computed tomography (CT) scan-based scoring system. Indices of lower airway remodeling and other markers of inflammation were also evaluated. RESULTS: Twenty-one patients with AERD were compared with 19 patients with aspirin-tolerant asthma (ATA). Patients were well matched for asthma severity as shown by their similar lung function as measured by postbronchodilator forced expiratory volume in 1 second. Patients with AERD were distinguished by their sinus CT scores (AERD patients: 16.9; 95% confidence interval [CI], 13.4-21.3; ATA patients: 6.2; 95% CI, 4.2-9.1; P < .001), and they were considerably more likely to have nasal polyps (AERD patients: 90%; ATA patients: 26%; P < .001). In addition, AERD patients demonstrated increased total lung capacity (AERD patients: 107.9%; 95% CI, 99.9%-117.6%; ATA patients: 98.0%; 95% CI, 93.7%-102.5%; P = .05), reflecting a trend toward increased air trapping. No significant differences occurred in diffusing capacity, exhaled nitric oxide, eosinophilia, or exhaled breath condensate pH. CONCLUSIONS: AERD can be distinguished from ATA by the extent of hyperplasia on CT scan and the presence of nasal polyps. We hypothesize that AERD represents a remodeling process that affects both the upper and lower airways. 相似文献
9.
Germline mutations of the CDKN2 gene in UK melanoma families 总被引:4,自引:1,他引:4
Harland M; Meloni R; Gruis N; Pinney E; Brookes S; Spurr NK; Frischauf AM; Bataille V; Peters G; Cuzick J; Selby P; Bishop DT; Bishop JN 《Human molecular genetics》1997,6(12):2061-2067
Germline mutations in CDKN2 on chromosome 9p21, which codes for the cyclin
D kinase inhibitor p16, and more rarely, mutations in the gene coding for
CDK4, the protein to which p16 binds, underlie susceptibility in some
melanoma families. We have sequenced all exons of CDKN2 and analysed the
CDK4 gene for mutations in 27 UK families showing evidence of
predisposition to melanoma. Five different germline mutations in CDKN2 were
found in six families. Three of the mutations (Met53Ile, Arg24Pro and
23ins24) have been reported previously. We have identified two novel CDKN2
mutations (88delG and Ala118Thr) which are likely to be associated with the
development of melanoma, because of their co-segregation with the disease
and their likely functional effect on the CDKN2 protein. In binding assays
the protein expressed from the previously described mutation, Met53Ile, did
not bind to CDK4/CDK6, confirming its role as a causal mutation in the
development of melanoma. Ala118Thr appeared to be functional in this assay.
Arg24Pro appeared to bind to CDK6, but not to CDK4. No mutations were
detected in exon 2 of CDK4, suggesting that causal mutations in this gene
are uncommon. The penetrance of these mutant CDKN2 genes is not yet
established, nor is the risk of non-melanoma cancer to gene carriers.
相似文献